These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12680167)

  • 1. beta tubulin mutations are rare in human ovarian carcinoma.
    Lamendola DE; Duan Z; Penson RT; Oliva E; Seiden MV
    Anticancer Res; 2003; 23(1B):681-6. PubMed ID: 12680167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues.
    Gréen H; Rosenberg P; Söderkvist P; Horvath G; Peterson C
    Cancer Lett; 2006 May; 236(1):148-54. PubMed ID: 16002208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
    Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
    Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.
    Mesquita B; Veiga I; Pereira D; Tavares A; Pinto IM; Pinto C; Teixeira MR; Castedo S
    BMC Cancer; 2005 Aug; 5():101. PubMed ID: 16095531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
    Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
    Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
    Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):854-9. PubMed ID: 16467099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
    Verdier-Pinard P; Wang F; Martello L; Burd B; Orr GA; Horwitz SB
    Biochemistry; 2003 May; 42(18):5349-57. PubMed ID: 12731876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR
    Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
    Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
    Isonishi S; Saitou M; Saitou M; Yasuda M; Tanaka T
    Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
    Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.
    Leonard DG; Travis LB; Addya K; Dores GM; Holowaty EJ; Bergfeldt K; Malkin D; Kohler BA; Lynch CF; Wiklund T; Stovall M; Hall P; Pukkala E; Slater DJ; Felix CA
    Clin Cancer Res; 2002 May; 8(5):973-85. PubMed ID: 12006509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.